阿斯利康:英飞凡获美国食品药品监督管理局批准,成为首个也是唯一一个围手术期免疫疗法,用于治疗早期胃癌和胃食管结合部癌患者。
阿斯利康:英飞凡获美国食品药品监督管理局批准,成为首个也是唯一一个围手术期免疫疗法,用于治疗早期胃癌和胃食管结合部癌患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.